A detailed history of Geode Capital Management, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,571,012 shares of AKRO stock, worth $48.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,571,012
Previous 1,619,039 2.97%
Holding current value
$48.1 Million
Previous $38 Million 18.67%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$21.45 - $29.34 $1.03 Million - $1.41 Million
-48,027 Reduced 2.97%
1,571,012 $45.1 Million
Q2 2024

Aug 09, 2024

BUY
$18.31 - $24.62 $3.66 Million - $4.92 Million
199,732 Added 14.07%
1,619,039 $38 Million
Q1 2024

May 13, 2024

BUY
$17.76 - $31.18 $4.49 Million - $7.89 Million
253,062 Added 21.7%
1,419,307 $35.9 Million
Q4 2023

Feb 13, 2024

BUY
$11.38 - $50.33 $716,245 - $3.17 Million
62,939 Added 5.7%
1,166,245 $27.2 Million
Q3 2023

Nov 13, 2023

BUY
$41.19 - $52.25 $11.5 Million - $14.6 Million
278,599 Added 33.78%
1,103,306 $55.8 Million
Q2 2023

Aug 11, 2023

BUY
$36.89 - $56.88 $5.86 Million - $9.03 Million
158,780 Added 23.84%
824,707 $38.5 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $50.24 $1.21 Million - $1.64 Million
32,547 Added 5.14%
665,927 $25.5 Million
Q4 2022

Feb 13, 2023

BUY
$33.44 - $54.8 $3.68 Million - $6.03 Million
110,091 Added 21.04%
633,380 $34.7 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $561,335 - $1.88 Million
55,304 Added 11.82%
523,289 $17.8 Million
Q2 2022

Aug 12, 2022

BUY
$8.0 - $15.01 $196,096 - $367,925
24,512 Added 5.53%
467,985 $4.42 Million
Q1 2022

May 13, 2022

BUY
$12.97 - $22.26 $347,492 - $596,389
26,792 Added 6.43%
443,473 $6.29 Million
Q4 2021

Feb 11, 2022

BUY
$19.87 - $26.24 $774,691 - $1.02 Million
38,988 Added 10.32%
416,681 $8.81 Million
Q3 2021

Nov 12, 2021

BUY
$18.65 - $25.46 $281,894 - $384,827
15,115 Added 4.17%
377,693 $8.44 Million
Q2 2021

Aug 13, 2021

BUY
$24.81 - $32.35 $2.43 Million - $3.17 Million
98,095 Added 37.09%
362,578 $9 Million
Q1 2021

May 12, 2021

BUY
$24.04 - $34.19 $548,616 - $780,249
22,821 Added 9.44%
264,483 $7.67 Million
Q4 2020

Feb 12, 2021

BUY
$25.12 - $29.89 $195,735 - $232,902
7,792 Added 3.33%
241,662 $6.23 Million
Q3 2020

Nov 13, 2020

BUY
$30.79 - $39.92 $2.89 Million - $3.75 Million
93,903 Added 67.09%
233,870 $7.2 Million
Q2 2020

Aug 13, 2020

BUY
$19.25 - $26.76 $501,655 - $697,365
26,060 Added 22.88%
139,967 $3.49 Million
Q1 2020

May 14, 2020

BUY
$12.8 - $27.05 $443,686 - $937,634
34,663 Added 43.74%
113,907 $2.41 Million
Q4 2019

Feb 13, 2020

BUY
$17.37 - $27.27 $81,864 - $128,523
4,713 Added 6.32%
79,244 $1.76 Million
Q3 2019

Nov 12, 2019

BUY
$16.89 - $29.88 $1.26 Million - $2.23 Million
74,531 New
74,531 $1.7 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.42B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.